The state of targeted therapeutic pharmacological approaches in pediatric neurosurgery: report from the European Society for Pediatric Neurosurgery (ESPN) Consensus Conference 2024
Child's Nervous System · 2025
DOI: 10.1007/s00381-025-06799-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Child's Nervous System, 2025. Verfasst von P Frassanito und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, 00168, Rome, Italy. paolo.frassanito@gmail.…. Hauptthemen laut MEDLINE: Brain Neoplasms, Pediatrics, Neurosurgery, Molecular Targeted Therapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università Cattolica del Sacro Cuore.
Abstract (Originalsprache)
Objective
The development of novel targeted therapies is opening new perspectives in the treatment of pediatric brain tumors. Their precise role in therapeutic protocols still needs still to be defined. Thus, these novel pharmacological approaches in pediatric neurosurgery were the topic of the European Society for Pediatric Neurosurgery (ESPN) Consensus Conference held in Lyon (France) in January 25–27, 2024.
Method
The paper reviews the current knowledge about targeted therapy as well as the current literature published on the topic. The conference aimed for an interdisciplinary consensus debate among pediatric oncologists and pediatric neurosurgeons on the following questions. Question 1: What is the current role for targeted therapies as neoadjuvant treatments before pediatric brain tumor removal? Question 2: What are the benefits, cost/efficiency, and long-term side effects of targeted therapies in the treatment of pediatric brain tumors? Question 3: Based on contemporary data, at which stage and in which pathologies do targeted therapies play a significant role?
Results
Ninety-two participants answered consensus polls on the state of the art of targeted therapies, the ethical issues related to their use, and the evolving change in the role of pediatric neurosurgeons. The neoadjuvant role of targeted therapies is difficult to define as there are many different entities to consider. Despite the recently reported potential benefits, questions regarding the use of targeted therapies are manifold, in particular regarding sustainable benefits and long-term side effects. Additionally, challenging cost issues is a limiting factor for the broader availability of these drugs. Studies have demonstrated superiority of targeted therapy compared to chemotherapy both in randomized trials and compared to historical cohorts in the management of a subset of low-grade gliomas. The same drug combinations, BRAFi and MEKi, may be effective in HGG that have relapsed, progressed, or failed to respond to first-line therapy. Similar conclusions on efficacy may be drawn for mTORi in TSC and selumetinib in plexiform neurofibromas. For other tumors, the picture is still obscure due to the lack of data or even the lack of suitable targets. In conclusion, targeted treatment may not always be the best option even when a target has been identified. Safe surgery remains to be a favorable option in the majority of cases.
Conclusion
The constantly evolving drug technology and the absence of long-term safety and efficacy studies made it difficult to reach a consensus on the predefined questions. However, a report of the conference is summarizing the present debate and it might serve as a guideline for future perspectives and ongoing research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, 00168, Rome, Italy. paolo.frassanito@gmail.com.
- Pediatric Neurosurgery, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany.
- Pediatric Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, 00168, Rome, Italy.
- Catholic University Medical School, Rome, Italy.
- Pediatric Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- Department of Pediatric Oncology, Institute of Pediatric Hematology and Oncology, Leon Berard Comprehensive Cancer Center, Lyon, France.
Förderung
- Università Cattolica del Sacro Cuore
Zitieren
APA
Frassanito, P., Thomale, U. W., Obersnel, M., Romano, A., Leblond, P., Knerlich-Lukoschus, F., Due-Tønnessen, B. J., Thompson, D., Di Rocco, F., & CPN Lyon 2024 Consensus Conference Group (2025). The state of targeted therapeutic pharmacological approaches in pediatric neurosurgery: report from the European Society for Pediatric Neurosurgery (ESPN) Consensus Conference 2024. Child's Nervous System. https://doi.org/10.1007/s00381-025-06799-0
Vancouver
Frassanito P, Thomale UW, Obersnel M, Romano A, Leblond P, Knerlich-Lukoschus F, et al. The state of targeted therapeutic pharmacological approaches in pediatric neurosurgery: report from the European Society for Pediatric Neurosurgery (ESPN) Consensus Conference 2024. Child's Nervous System. 2025. doi:10.1007/s00381-025-06799-0
BibTeX
@article{Frassanito2025,
author = {Frassanito, P and Thomale, U W and Obersnel, M and Romano, A and Leblond, P and Knerlich-Lukoschus, F and Due-Tønnessen, B J and Thompson, D and Di Rocco, F and CPN Lyon 2024 Consensus Conference Group, CPN Lyon 2024 Consensus Conference Group},
title = {The state of targeted therapeutic pharmacological approaches in pediatric neurosurgery: report from the European Society for Pediatric Neurosurgery (ESPN) Consensus Conference 2024},
journal = {Child's Nervous System},
year = {2025},
doi = {10.1007/s00381-025-06799-0}
}
EUVIMED